PBI18 BIOLOGIC THERAPIES FOR MODERATE-TO-SEVERE PSORIASIS: COST PER RESPONDER ANALYSIS CONSIDERING PRIVATE HEALTHCARE SYSTEM IN BRAZIL.

To assess the cost-per-responder of biologic therapies available in Brazil to treat moderate-to-severe plaque psoriasis (PsO) using as outcomes a reduction of 75%, 90%, and 100% in Psoriasis Area and Severity Index (PASI 75/90/100). Conclusions Among the evaluated biologic therapies, risankizumab was associated with lowest cost-per-responder in all analyzed PASI outcomes, with more pronounced difference in higher PASI responses, considering Brazilian private healthcare system. [Extracted from the article]